A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Trial Profile

A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Carcinoma; Endometrial cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Head and neck cancer; Neuroendocrine tumours; Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms Basket
  • Sponsors PharmaMar
  • Most Recent Events

    • 12 Sep 2017 Results of a pooled analysis assessing the Antitumor activity of Lurbinectedin in patient from three trials (NCT01970540, NCT02454972 and one more study; n=83) of presented at the 42nd European Society for Medical Oncology Congress
    • 24 Apr 2017 Planned number of patients changed from 250 to 325.
    • 07 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top